Trials / Completed
CompletedNCT04515576
A Study of LY3493269 in Participants With Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will last up to approximately 16 weeks for each participant and may include up to 11 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3493269 | Administered SC |
| DRUG | Dulaglutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2020-08-25
- Primary completion
- 2021-03-09
- Completion
- 2021-03-09
- First posted
- 2020-08-17
- Last updated
- 2025-01-14
- Results posted
- 2025-01-14
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04515576. Inclusion in this directory is not an endorsement.